<DOC>
	<DOCNO>NCT00117351</DOCNO>
	<brief_summary>This study evaluate safety efficacy VELCADE patient previously treat stage IIIB IV bronchioloalveolar carcinoma adenocarcinoma bronchioloalveolar feature .</brief_summary>
	<brief_title>VELCADE Previously Treated Patients With Stage IIIB IV Bronchioloalveolar Carcinoma ( BAC ) Adenocarcinoma With BAC Features</brief_title>
	<detailed_description>Bronchioloalveolar carcinoma ( BAC ) adenocarcinoma bronchioloalveolar feature distinct subtypes non-small-cell lung cancer difficult treat advance stage . This study determine safety efficacy VELCADE therapy patient advance BAC adenocarcinoma BAC feature fail epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ) therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Have histologically cytologically confirm BAC adenocarcinoma BAC feature . Have stage IIIB ( malignant pleural effusion ) stage IV disease . Have progress receipt 1 2 prior line chemotherapy , one must EGFR TKI ( Iressa Tarceva ) . Adjuvant chemotherapy NOT count prior line therapy . Have radiographic documentation progressive disease ( PD ) determine investigator . Have measurable disease RECIST . Are 18 year age old . Have life expectancy great 3 month . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Are able provide write informed consent accordance applicable regulation follow study procedure . Patients must capable understanding investigational nature potential risk benefit . Have chemotherapy ( EGFR TKI ) 4 week prior enrollment . Have peripheral neuropathy Grade 2 great intensity , define National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE 3.0 ) . Have previously treat VELCADE . Have experience myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Have radiation therapy within 4 week prior enrollment . Have monoclonal antibody therapy within 4 week prior enrollment . Have major surgery within 4 week prior enrollment . Have inadequate organ function Screening visit define laboratory test Have symptomatic brain metastasis brain metastasis respond radiation therapy , local systemic chemotherapy , completely resect stereotactic surgery surgical modality , significant post treatment brain edema . Have uncontrolled active systemic infection require treatment . Have treatment cancer BAC within 5 year prior enrollment , exception basal cell carcinoma cervical cancer situ . Have history allergic reaction attributable compound contain boron mannitol hypersensitivity reaction drug formulate polysorbate 80 . Have know human immunodeficiency virus ( HIV ) positive hepatitis B surface antigenpositive status know active hepatitis C infection . Patients assess investigator risk HIV , hepatitis B C infection test accordance local regulation . Have poorly control hypertension , diabetes mellitus , another serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Are pregnant breastfeed female . Confirmation patient pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening period . Pregnancy test require postmenopausal surgically sterilize woman . Are unwilling employ adequate mean contraception ( condom , diaphragm , birth control pill , injection , intrauterine device , abstinence ) . Are currently receive previously receive investigational agent reason within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Bronchiolo-Alveolar</keyword>
	<keyword>Carcinoma , Bronchioloalveolar</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Carcinoma , Bronchiolo-Alveolar</keyword>
</DOC>